";s:4:"text";s:5393:" Amalgamated Bank now owns 6,436 shares of the biotechnology company’s stock worth $264,000 after purchasing an additional 254 shares during the period.
Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. REGENXBIO Inc. analyst estimates by MarketWatch.
Get short term trading ideas from the MarketBeat Idea Engine. Royal Bank of Canada assumed coverage on shares of Regenxbio in a research report on Tuesday, May 12th.
The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. Mutual of America Capital Management LLC now owns 1,371 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 294 shares during the period.
Regenxbio Inc (NASDAQ:RGNX) has been assigned a consensus recommendation of “Buy” from the ten analysts that are currently covering the firm, MarketBeat Ratings reports. Learn about financial terms, types of investments, trading strategies and more.MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. High institutional ownership can be a signal of strong market trust in this company.Earnings for Regenxbio are expected to grow in the coming year, from ($2.87) to ($1.72) per share.The P/E ratio of Regenxbio is -12.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.The P/E ratio of Regenxbio is -12.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Regenxbio has a P/B Ratio of 2.81. Top institutional investors include Botty Investors LLC (0.81%), UBS Group AG (0.81%), P.A.W.
Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Regenxbio has received a consensus rating of Buy. Oregon Public Employees Retirement Fund now owns 12,658 shares of the biotechnology company’s stock worth $466,000 after purchasing an additional 300 shares during the period. The sale was disclosed in a filing with the SEC, which can be accessed through A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock.
The biotechnology company earns $-94,730,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis. 6 brokers have issued 12-month price targets for Regenxbio's stock.
7 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Regenxbio in the last year. Since then, RGNX shares have increased by 4.4% and is now trading at $34.33. REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Please log in to your account or sign up in order to add this asset to your watchlist. Specifically, they have bought $0.00 in company stock and sold $900,755.00 in company stock.Only 14.10% of the stock of Regenxbio is held by insiders.76.68% of the stock of Regenxbio is held by institutions. RGX-314 is our product candidate for the treatment of wet age-related macular degeneration (AMD). 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year.
Enter your email address below to get the latest news and analysts' ratings for Regenxbio with our FREE daily email newsletter:
All rights reserved.
Alliancebernstein L.P. grew its stake in Regenxbio by 0.3% during the fourth quarter. & Chief Technology Officer Export data to Excel for your own analysis. The business's quarterly revenue was up 1855.6% on a year-over-year basis. "Regenxbio's stock is owned by a number of retail and institutional investors. Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista.
RGNX stock was purchased by a variety of institutional investors in the last quarter, including P.A.W. Regenxbio had a negative net margin of 197.23% and a negative return on equity of 27.84%. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.87) by $0.21.
On average, they anticipate Regenxbio's stock price to reach $68.33 in the next twelve months.
